ArticleMolecular oncology2020

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.

Dinja T Kruger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.